RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • Regulatory NewsRegulatory News

    FDA’s COVID-19 vaccine adcomm raises questions as first readouts loom

    With several COVID-19 vaccine candidates nearing Phase 3 readouts and the prospect that one or more could receive emergency use authorization (EUA) before the end of the year, advisors to the US Food and Drug Administration (FDA) met on Thursday to deliberate the standards the agency has set for authorization or licensure of a vaccine.   In a nine-hour public meeting meant to provide transparency and build public confidence in the process surrounding COVID-19 vaccine d...
  • ReconRecon

    Recon: AstraZeneca’s COVID vaccine packs a wallop; Merck KGaA, partners link for COVID mAbs

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Facing vaccine doubts, US grapples with building confidence in coronavirus shots ( BioPharma Dive ) FDA shows signs of cold feet over emergency authorization of Covid-19 vaccines ( STAT ) How pandemic fatigue and polarization led to Wisconsin’s massive Covid-19 outbreak ( Vox ) ( NPR ) Report finds coronavirus pandemic leading to 'unacceptable' shortage of US ...
  • Regulatory NewsRegulatory News

    FDA plans master protocols to monitor COVID vaccine safety, efficacy

    After a vaccine against COVID-19 is authorized or approved, how will its safety and efficacy be assessed? In addition to ongoing postmarket surveillance requirements, the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) will strive for near real-time safety and efficacy surveillance of COVID-19 vaccines.   FDA is currently developing master protocols to guide its safety and effectiveness oversight, said an FDA official duri...
  • Regulatory NewsRegulatory News

    Remdesivir receives FDA approval for COVID-19

    The US Food and Drug Administration (FDA) has given full approval to the first drug to treat COVID-19. The antiviral Veklury (remdesivir, Gilead Sciences) received approval on 22 October to treat older children and adults who are hospitalized with COVID-19.   Veklury had previously received an emergency use authorization EUA on 1 May 2020 for a broader population that also included hospitalized pediatric patients weighing 3.5 kg or more.   "The FDA is committed to ...
  • ReconRecon

    Recon: Moderna completes enrollment in Phase 3 COVID vaccine study; Dr Reddy’s hit by cyberattack

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US An angry Azar floats plans to oust FDA’s Hahn ( Politico ) Moderna completes enrollment in large COVID-19 vaccine study ( Reuters ) Roche, Atea team up on potential COVID-19 pill ( Reuters ) US likely to have enough COVID-19 vaccines for all vulnerable Americans by year end: official ( Reuters ) Why the US doesn’t have an at-home coronavirus test yet ( Politi...
  • Regulatory NewsRegulatory News

    FDA’s COVID-focused vaccines adcomm: A preview

    On 22 October, the US Food and Drug Administration (FDA) will convene the first COVID-19-focused meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC).   The meeting is not reviewing information about a specific vaccine; rather, the committee is convening “to discuss, in general, the development, authorization and/or licensure of vaccines to prevent COVID-19,” according to the agenda . The committee is tasked with sorting through much tec...
  • Regulatory NewsRegulatory News

    FDA approves fewer generics in FY2020, ending record streak

    After four straight years of posting record numbers of abbreviated new drug application (ANDA) approvals, the US Food and Drug Administration (FDA) has broken its streak, approving 22% fewer generic drugs in FY2020 than it did in FY2019.   In FY2020, FDA approved a total of 909 ANDAs, 737 full approvals and 172 tentative approvals, compared to a record 1,171 ANDAs in FY2019. Complete responses also declined to 2,010 compared to 2,310 in FY2019. (RELATED: Another reco...
  • Participants sought for FDA nonclinical data exchange pilot

    The US Food and Drug Administration (FDA) is seeking volunteers to participate in a fit for use pilot program of electronic processing and analysis of nonclinical study data in developmental and reproductive toxicology.   The pilot will look at data provided electronically for the Clinical Data Interchange Standards Consortium (CDISC) for Standard for Exchange of Nonclinical Data implementation guide for Developmental and Reproductive Toxicology version 1.1 (SEND-DART)...
  • RoundupsRoundups

    FDA Approvals Roundup: Inmazeb, Wakix, Venclexta

    A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).   New approvals Inmazeb approved as first treatment for Ebola virus Regeneron’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn combination) has been approved as the first treatment for Zaire ebolavirus (Ebola virus) infection in adults and children. The therapy received orphan drug and breakthrough therapy designations for treating the infection.   ...
  • ReconRecon

    Recon: Purdue pleads guilty to criminal charges over opioid sales; EU signs deal for J&J COVID vaccine

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Purdue Pharma Pleads Guilty to Criminal Charges for Opioid Sales ( NYTimes ) AstraZeneca close to restarting Covid-19 vaccine trial in US ( Politico ) ( Reuters ) Covid-19 vaccine researchers left in the dark as trials remain on hold ( NBC ) Lilly hires external adviser for COVID-19 drug plant problems ( Reuters ) ( Bloomberg ) States prepare for their own va...
  • Regulatory NewsRegulatory News

    IMDRF proposes update on postmarketing device studies

    The International Medical Device Regulators Forum has issued a proposed update to its guidance on postmarket clinical follow-up (PMCF) studies for medical devices, with advice on the design, implementation, and appropriate use of these studies.   The update outlines when a PMCF study is indicated, the general principles of PMCF studies for medical devices, the design and implementation of studies, and the use of the clinical information. The document does not apply t...
  • Regulatory NewsRegulatory News

    With new guidance, FDA moves toward uniform postmarketing reporting

    A new draft guidance related to postmarketing requirements and commitments is available from the US Food and Drug Administration (FDA). The document details how drug and biologics marketers will use two forms for online submission of annual status report and other required postmarketing information.   The forms, FDA 3988 and 3989, are the mechanisms by which applicants will fulfill requirements for annual reporting on the status of postmarketing requirements (PMRs) and...